Tags

Type your tag names separated by a space and hit enter

New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection.
Clin Microbiol Infect. 2020 Sep; 26(9):1236-1241.CM

Abstract

OBJECTIVES

We investigated the prevalence of anosmia and ageusia in adult patients with a laboratory-confirmed diagnosis of infection with severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2).

METHODS

This was a retrospective observational analysis of patients infected with SARS-CoV-2 admitted to hospital or managed in the community and their household contacts across a London population during the period March 1st to April 1st, 2020. Symptomatology and duration were extracted from routinely collected clinical data and follow-up telephone consultations. Descriptive statistics were used.

RESULTS

Of 386 patients, 141 (92 community patients, 49 discharged inpatients) were included for analysis; 77/141 (55%) reported anosmia and ageusia, nine reported only ageusia and three only anosmia. The median onset of anosmia in relation to onset of SARS-CoV-2 disease (COVID-19) symptoms (as defined by the Public Health England case definition) was 4 days (interquartile range (IQR) 5). Median duration of anosmia was 8 days (IQR 16). Median duration of COVID-19 symptoms in community patients was 10 days (IQR 8) versus 18 days (IQR 13.5) in admitted patients. As of April 1, 45 patients had ongoing COVID-19 symptoms and/or anosmia; 107/141 (76%) patients had household contacts, and of 185 non-tested household contacts 79 (43%) had COVID-19 symptoms with 46/79 (58%) reporting anosmia. Six household contacts had anosmia only.

CONCLUSIONS

Over half of the positive patients reported anosmia and ageusia, suggesting that these should be added to the case definition and used to guide self-isolation protocols. This adaptation may be integral to case findings in the absence of population-level testing. Until we have successful population-level vaccination coverage, these steps remain critical in the current and future waves of this pandemic.

Authors+Show Affiliations

Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK.Imperial College London, NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK. Electronic address: e.charani@imperial.ac.uk.Imperial College London School of Medicine, Kensington, London, SW7 2DD, UK.Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK.Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK; North West London Pathology, Fulham Palace Road, London, W6 8RF, UK.Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK; Imperial College London, NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK; North West London Pathology, Fulham Palace Road, London, W6 8RF, UK.Chelsea and Westminster NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK; Imperial College London, NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK; North West London Pathology, Fulham Palace Road, London, W6 8RF, UK.

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

32502645

Citation

Patel, A, et al. "New-onset Anosmia and Ageusia in Adult Patients Diagnosed With SARS-CoV-2 Infection." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 26, no. 9, 2020, pp. 1236-1241.
Patel A, Charani E, Ariyanayagam D, et al. New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection. Clin Microbiol Infect. 2020;26(9):1236-1241.
Patel, A., Charani, E., Ariyanayagam, D., Abdulaal, A., Denny, S. J., Mughal, N., & Moore, L. S. P. (2020). New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 26(9), 1236-1241. https://doi.org/10.1016/j.cmi.2020.05.026
Patel A, et al. New-onset Anosmia and Ageusia in Adult Patients Diagnosed With SARS-CoV-2 Infection. Clin Microbiol Infect. 2020;26(9):1236-1241. PubMed PMID: 32502645.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection. AU - Patel,A, AU - Charani,E, AU - Ariyanayagam,D, AU - Abdulaal,A, AU - Denny,S J, AU - Mughal,N, AU - Moore,L S P, Y1 - 2020/06/02/ PY - 2020/05/05/received PY - 2020/05/23/revised PY - 2020/05/26/accepted PY - 2020/6/6/pubmed PY - 2020/12/23/medline PY - 2020/6/6/entrez KW - Ageusia KW - Anosmia KW - COVID-19 KW - Coronavirus KW - Ear nose and throat [MeSH] KW - SARS-CoV-2 SP - 1236 EP - 1241 JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JO - Clin Microbiol Infect VL - 26 IS - 9 N2 - OBJECTIVES: We investigated the prevalence of anosmia and ageusia in adult patients with a laboratory-confirmed diagnosis of infection with severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2). METHODS: This was a retrospective observational analysis of patients infected with SARS-CoV-2 admitted to hospital or managed in the community and their household contacts across a London population during the period March 1st to April 1st, 2020. Symptomatology and duration were extracted from routinely collected clinical data and follow-up telephone consultations. Descriptive statistics were used. RESULTS: Of 386 patients, 141 (92 community patients, 49 discharged inpatients) were included for analysis; 77/141 (55%) reported anosmia and ageusia, nine reported only ageusia and three only anosmia. The median onset of anosmia in relation to onset of SARS-CoV-2 disease (COVID-19) symptoms (as defined by the Public Health England case definition) was 4 days (interquartile range (IQR) 5). Median duration of anosmia was 8 days (IQR 16). Median duration of COVID-19 symptoms in community patients was 10 days (IQR 8) versus 18 days (IQR 13.5) in admitted patients. As of April 1, 45 patients had ongoing COVID-19 symptoms and/or anosmia; 107/141 (76%) patients had household contacts, and of 185 non-tested household contacts 79 (43%) had COVID-19 symptoms with 46/79 (58%) reporting anosmia. Six household contacts had anosmia only. CONCLUSIONS: Over half of the positive patients reported anosmia and ageusia, suggesting that these should be added to the case definition and used to guide self-isolation protocols. This adaptation may be integral to case findings in the absence of population-level testing. Until we have successful population-level vaccination coverage, these steps remain critical in the current and future waves of this pandemic. SN - 1469-0691 UR - https://www.unboundmedicine.com/medline/citation/32502645/New_onset_anosmia_and_ageusia_in_adult_patients_diagnosed_with_SARS_CoV_2_infection_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1198-743X(20)30303-7 DB - PRIME DP - Unbound Medicine ER -